Abstract Library

#4282 A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas

Introduction: Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.

Conference:

Presenting Author: Del Rivero J

Authors: Del Rivero J, Glod J, Magee T, Cooper K, Rivero A,

Keywords: NEN, NEC, NET, ACC, ADC, ADCT-701,

#4012 14 years of the Czech Neuroendocrine Tumors Registry

Introduction: Czech Cooperative Group for NETs was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group founded 1998. The Czech Neuroendocrine Registry was started in 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.

Conference:

Presenting Author:

Authors: Barkmanova J, Sedlackova E,

Keywords: neuroendocrine registry, population-based system, neuroendocrine tumor (NET),

#3341 A rare case of oligometastatic thymic carcinoid

Introduction: Primary thymic neuroendocrine tumors (NETs) are a rare type of cancer which have a propensity to local or distant spread to nodes, lung, and bone. Treatment consists of a combination of surgery, SACT and radiotherapy, depending on the stage.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cooper J

Authors: Cooper J, Jethwa D, Zen Y, Prachalis A, Taylor B,

Keywords: thymic carcinoid, oligometastatic disease,

#3309 Comprehensive genetic analysis of tumor suppressor genes Men1, PTEN, Rb1 and p53 in NETs in mice

Introduction: Tumor suppressor genes (TSGs) RB1, TP53 and PTEN are three of the most commonly mutated TSGs in human cancers. Multiple endocrine neoplasia type 1 (MEN1) gene is one of the most frequently mutated TSGs in human neuroendocrine tumors (NETs). Cooperative effects of genetic alterations of TSGs are frequently observed during carcinogenesis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Xu E, Vosburgh E, Wong C, Tang L, Levine A,

Keywords: neuroendocrine tumor, men1, rb, pten, p53,

#3262 Real-world effectiveness and serotonin reduction in patients with progressive neuroendocrine tumors and carcinoid syndrome receiving telotristat ethyl

Introduction: Clinical trials have demonstrated the efficacy and safety of telotristat ethyl (TE) treatment in combination with somatostatin analogues (SSAs) in patients with neuroendocrine tumors (NETs) and inadequately controlled carcinoid syndrome (CS) diarrhea. The TELEACE study was designed to evaluate the real-world effectiveness of TE in US clinical practice.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Liu E

Authors: Liu E, Giacalone S, Joish V, Dharba S, Yarkoni T,

Keywords: neuroendocrine tumor, carcinoid syndrome, telotristat ethyl, serotonin,